Development asset linked to Spyre Therapeutics in public FDA and regional records.
pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE
Spyre Therapeutics
Spyre Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, USA HQ
2023 Founded
110 Employees
Public company Type
SYRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2023
- Employees
- 110
- Programs
- 8
- Drugs
- 1
- Patents
- 0
Spyre Therapeutics pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Spyre Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.